Table 3.
Immunohistochemical Staining Results for p16INK4a, Cyclin D, and RB in Tumor Sections and Efficacy Endpoints.
| Time to Progression (Days) | Best Response* | Dose Level | Oropharynx Y/N | p16 Status | Cyclin D1 (nuclear) | Rb | Cetuximab - Resistant | Platin- Resistant |
|---|---|---|---|---|---|---|---|---|
| 224 | PRa | 2 | No | Negative | Positive | Positive | N | N |
| 224 | SDb | 1 | Yes | Positive | Positive | Positive | N | N |
| 168 | SD | 1 | Yes | Negative | Positive | Positive | Y | N |
| 168 | SD | 2 | No | Positive | Positive | Positive | N | N |
| 112 | PR | 2 | No | Negative | Positive | Positive | Y | Y |
| 112 | SD | 1 | No | Negative | Positive | Positive | Y | N |
| 112 | SD | 2 | Yes | Positive | Negative | Positive | Y | Y |
| 112 | SD | 2 | No | Negative | Positive | Positive | Y | Y |
| 28 | PDc | 2 | Yes | Positive | Not Doned | Not Doned | Y | Y |
a
PR=Partial Response
b
SD=Stable Disease
c
PD=Progressive Disease
d
Insufficient tissue